Search results
Vertex Pharmaceuticals Q1 2024 Earnings: Surpasses Revenue Expectations with Strategic Expansions
GuruFocus.com via Yahoo Finance· 2 minutes agoStrategic Acquisition: Announced the acquisition of Alpine Immune Sciences, enhancing the pipeline...
Vertex earnings beat by $0.68, revenue topped estimates By Investing.com
Investing.com· 2 hours agoVertex earnings beat by $0.68, revenue topped estimates
Vertex Beats Quarterly Forecasts, But Its Pipeline Remains Key
Investor's Business Daily· 46 minutes agoAlthough Vertex Pharmaceuticals (VRTX) is the de facto leader of the market for cystic fibrosis...
Vertex shares eise on earnings beat
Investing.com· 17 hours agoVertex Pharmaceuticals (NASDAQ: VRTX ) Incorporated ( NASDAQ : VRTX) reported a robust first quarter for 2024, surpassing analyst expectations with a 13%...
Vertex tops Q1 profit estimates on robust demand for cystic fibrosis treatments
WHTC 1450 Holland· 1 hour ago(Reuters) - Vertex Pharmaceuticals beat Wall Street estimates for first-quarter profit on Monday,...
Vertex: Q1 Earnings Snapshot
Houston Chronicle· 1 hour agoBOSTON (AP) — BOSTON (AP) — Vertex Pharmaceuticals Inc. (VRTX) on Monday reported...
Vertex Pharmaceuticals (NASDAQ:VRTX) Raised to “Strong-Buy” at StockNews.com
ETF DAILY NEWS· 20 hours agoBarclays raised their price objective on shares of Vertex Pharmaceuticals from $446.00 to $472.00 and gave the stock an overweight rating in a research report on Tuesday, ...
3 Biotech Stocks to Double Your Money in the Next 24 Months
InvestorPlace· 3 hours agoThe biotechnology sector is renowned for its potential to deliver groundbreaking medical treatments...
Dow Jones Futures: AI Stock Palantir Plunges On Earnings; Apple 'Let Loose' Event Next
Investor's Business Daily· 7 minutes agoShares of the AI leader surged 8.1% Monday to retake their 50-day line. Other key earnings movers...
CRISPR (CRSP) to Report Q1 Earnings: What's in the Cards?
Zacks via Yahoo Finance· 5 hours agoOn CRISPR Therapeutics' (CRSP) first-quarter 2024 earnings call, investors' focus is likely to be on...
